Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Selection of Unrelated Donors and Cord Blood Units for Hematopoietic Cell Transplantation: Guidelines from NMDP/CIBMTR.

Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, Confer DL, Eapen M, Fernandez-Vina MA, Hartzman R, Maiers M, Marino SR, Mueller C, Perales MA, Rajalingam R, Pidala J.

Blood. 2019 Jul 10. pii: blood.2019001212. doi: 10.1182/blood.2019001212. [Epub ahead of print]

PMID:
31292117
2.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Jun 28. doi: 10.1158/1078-0432.CCR-18-3988. [Epub ahead of print]

PMID:
31253630
3.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W.

Blood Adv. 2019 Jun 25;3(12):1826-1836. doi: 10.1182/bloodadvances.2019000050.

4.

Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S.

Biol Blood Marrow Transplant. 2019 May 31. pii: S1083-8791(19)30330-1. doi: 10.1016/j.bbmt.2019.05.019. [Epub ahead of print]

PMID:
31158502
5.

Regarding "Recipients Receiving Better HLA-Matched Hematopoietic Cell Transplantation Grafts, Uncovered by a Novel HLA Typing Method, Have Superior Survival: A Retrospective Study".

Hurley CK, Spellman S, Dehn J, Barker JN, Devine S, Fernandez-Vina M, Gautreaux M, Logan B, Maiers M, Mueller C, Perales MA, Yu N, Pidala J.

Biol Blood Marrow Transplant. 2019 May 27. pii: S1083-8791(19)30337-4. doi: 10.1016/j.bbmt.2019.05.026. [Epub ahead of print] No abstract available.

PMID:
31145991
6.

Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.

Martin PJ, Storer BE, Palmer J, Jagasia MH, Chen GL, Broady R, Arora M, Pidala JA, Hamilton BK, Lee SJ.

Biol Blood Marrow Transplant. 2019 May 11. pii: S1083-8791(19)30293-9. doi: 10.1016/j.bbmt.2019.05.008. [Epub ahead of print]

PMID:
31085305
7.

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S.

Biol Blood Marrow Transplant. 2019 May 11. pii: S1083-8791(19)30291-5. doi: 10.1016/j.bbmt.2019.05.007. [Epub ahead of print]

PMID:
31085303
8.

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ.

Blood Adv. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.

9.

Worsening cognitive performance is associated with increases in systemic inflammation following hematopoietic cell transplantation.

Hoogland AI, Nelson AM, Gonzalez BD, Small BJ, Breen EC, Sutton SK, Syrjala KL, Bower JE, Pidala J, Booth-Jones M, Jacobsen PB, Jim HSL.

Brain Behav Immun. 2019 Apr 3. pii: S0889-1591(18)30512-9. doi: 10.1016/j.bbi.2019.04.008. [Epub ahead of print]

PMID:
30953767
10.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
11.

Circadian Rhythmicity as a Predictor of Quality of Life in Allogeneic Hematopoietic Cell Transplant Patients.

Hoogland AI, Bulls HW, Gonzalez BD, Small BJ, Liu L, Pidala J, Jim HSL, Mishra A.

J Pain Symptom Manage. 2019 May;57(5):952-960.e1. doi: 10.1016/j.jpainsymman.2019.01.015. Epub 2019 Jan 31.

PMID:
30711631
12.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CH, Frieling J, Lynch CC, List A, Rodriguez PC, Blazar BR, Conejo-Garcia JR, Del Valle JR, Hu CC, Anasetti C.

Front Immunol. 2018 Dec 6;9:2887. doi: 10.3389/fimmu.2018.02887. eCollection 2018.

13.

Understanding preferences for a mindfulness-based stress management program among caregivers of hematopoietic cell transplant patients.

Vinci C, Reblin M, Jim H, Pidala J, Bulls H, Cutolo E.

Complement Ther Clin Pract. 2018 Nov;33:164-169. doi: 10.1016/j.ctcp.2018.10.007. Epub 2018 Oct 17.

PMID:
30396616
14.

Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America.

Khera N, Hamilton BK, Pidala JA, Wood WA, Wu V, Voutsinas J, Onstad L, Alousi AM, Broady R, Chen GL, Arora M, Cutler C, Flowers ME, Ganetsky A, Jagasia M, McCarthy PL, Sarantopoulos S, Abel GA, Majhail NS, Lee SJ.

Biol Blood Marrow Transplant. 2019 Mar;25(3):599-605. doi: 10.1016/j.bbmt.2018.09.040. Epub 2018 Oct 5.

PMID:
30296479
15.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini P, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfan-Dabaja MA, Litzow MR, Ringden O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2019 Feb;25(2):270-278. doi: 10.1016/j.bbmt.2018.09.004. Epub 2018 Oct 3.

PMID:
30292009
16.

Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies.

Gandelman JS, Byrne MT, Mistry AM, Polikowsky HG, Diggins KE, Chen H, Lee SJ, Arora M, Cutler C, Flowers M, Pidala J, Irish JM, Jagasia MH.

Haematologica. 2019 Jan;104(1):189-196. doi: 10.3324/haematol.2018.193441. Epub 2018 Sep 20.

17.

The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.

Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER.

Biol Blood Marrow Transplant. 2019 Feb;25(2):279-286. doi: 10.1016/j.bbmt.2018.09.007. Epub 2018 Sep 13.

PMID:
30219700
18.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.

PMID:
30194027
19.

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.

Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.

Biol Blood Marrow Transplant. 2019 Jan;25(1):73-85. doi: 10.1016/j.bbmt.2018.08.018. Epub 2018 Aug 25.

PMID:
30153491
20.

Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Yingst A, Couriel D, Alousi A, Pidala J, Knight JM, Verneris MR.

Biol Blood Marrow Transplant. 2019 Jan;25(1):12-18. doi: 10.1016/j.bbmt.2018.08.011. Epub 2018 Aug 23.

PMID:
30144561
21.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

22.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated.

Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, Horowitz M, Alousi A, Couriel D, Pidala J, Arora M, Cutler C; GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee.

Haematologica. 2018 Oct;103(10):1708-1719. doi: 10.3324/haematol.2017.182550. Epub 2018 Aug 3.

23.

In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance.

Arrieta-Bolaños E, Crivello P, Shaw BE, Ahn KW, Wang HL, Verneris MR, Hsu KC, Pidala J, Lee SJ, Fleischhauer K, Spellman SR.

Blood Adv. 2018 Jul 24;2(14):1773-1783. doi: 10.1182/bloodadvances.2018019620.

24.

Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease.

El-Jawahri A, Pidala J, Khera N, Wood WA, Arora M, Carpenter PA, Palmer J, Flowers ME, Jagasia M, Chen YB, Lee SJ.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2285-2292. doi: 10.1016/j.bbmt.2018.07.020. Epub 2018 Jul 20.

PMID:
30031937
25.

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2019 Jan;54(1):85-89. doi: 10.1038/s41409-018-0233-2. Epub 2018 Jun 12.

PMID:
29895929
26.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW.

Blood Adv. 2018 May 8;2(9):1022-1031. doi: 10.1182/bloodadvances.2017013052. Erratum in: Blood Adv. 2018 Jun 12;2(11):1294.

27.

Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.

Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, Powers J, Sahakian E, Villagra A, Mishra A, Betts B, Kharfan-Dabaja M, Beato F, Ochoa-Bayona L, Pidala J, Anasetti C.

Bone Marrow Transplant. 2018 Nov;53(11):1434-1444. doi: 10.1038/s41409-018-0163-z. Epub 2018 Apr 18.

PMID:
29670210
28.

ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.

Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, Shah N, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.

29.

Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most.

Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, Horowitz MM, Verneris M, Hsu KC, Fleischhauer K, Lee SJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1049-1056. doi: 10.1016/j.bbmt.2018.02.006. Epub 2018 Feb 14.

30.

Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.

Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR.

Bone Marrow Transplant. 2018 Jul;53(7):932-937. doi: 10.1038/s41409-018-0100-1. Epub 2018 Jan 30. No abstract available.

31.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.

Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1582-1587. doi: 10.1073/pnas.1712452115. Epub 2018 Jan 30.

32.

Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.

Kharfan-Dabaja MA, Sheets K, Kumar A, Murthy HS, Nishihori T, Tsalatsanis A, Mina A, Mathews J, Ayala E, Chavez J, Perez LE, Betts BC, Anasetti C, Pidala J.

Br J Haematol. 2018 Mar;180(6):854-862. doi: 10.1111/bjh.15105. Epub 2018 Jan 18.

PMID:
29345306
33.

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.

Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JLM, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C.

Haematologica. 2018 Mar;103(3):531-539. doi: 10.3324/haematol.2017.171199. Epub 2017 Dec 14.

34.

Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis.

Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J.

Biol Blood Marrow Transplant. 2018 Mar;24(3):521-528. doi: 10.1016/j.bbmt.2017.11.004. Epub 2017 Nov 16.

35.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB.

J Clin Oncol. 2017 Dec 20;35(36):4003-4011. doi: 10.1200/JCO.2017.75.8177. Epub 2017 Oct 17.

PMID:
29040031
36.

Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.

Hamilton BK, Rybicki L, Arai S, Arora M, Cutler CS, Flowers MED, Jagasia M, Martin PJ, Palmer J, Pidala J, Majhail NS, Lee SJ, Khera N.

Biol Blood Marrow Transplant. 2018 Feb;24(2):393-399. doi: 10.1016/j.bbmt.2017.10.009. Epub 2017 Oct 12.

37.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA.

Biol Blood Marrow Transplant. 2018 Feb;24(2):400-405. doi: 10.1016/j.bbmt.2017.09.022. Epub 2017 Oct 13.

38.

Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation.

Fleischhauer K, Ahn KW, Wang HL, Zito L, Crivello P, Müller C, Verneris M, Shaw BE, Pidala J, Oudshorn M, Lee SJ, Spellman SR.

Bone Marrow Transplant. 2017 Sep;52(9):1280-1287. doi: 10.1038/bmt.2017.96. Epub 2017 Jun 5.

39.

An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ.

Blood. 2017 Jul 20;130(3):360-367. doi: 10.1182/blood-2017-03-775767. Epub 2017 May 11.

40.

Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning.

Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM.

Am J Epidemiol. 2017 Jul 15;186(2):160-172. doi: 10.1093/aje/kwx027.

PMID:
28472335
41.

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J.

Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. doi: 10.1038/bmt.2017.63. Epub 2017 Apr 3.

PMID:
28368376
42.

Improved survival after acute graft-versus-host disease diagnosis in the modern era.

Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J.

Haematologica. 2017 May;102(5):958-966. doi: 10.3324/haematol.2016.156356. Epub 2017 Mar 16.

43.

A combined biomarker and clinical panel for chronic graft versus host disease diagnosis.

Pidala J, Sigdel TK, Wang A, Hsieh S, Inamoto Y, Martin PJ, Flowers ME, Hansen JA, Lee SJ, Sarwal MM.

J Pathol Clin Res. 2016 Nov 29;3(1):3-16. doi: 10.1002/cjp2.58. eCollection 2017 Jan.

44.

IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.

Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C.

Haematologica. 2017 May;102(5):948-957. doi: 10.3324/haematol.2016.153072. Epub 2017 Jan 19.

45.

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.

Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaai8269. doi: 10.1126/scitranslmed.aai8269.

46.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.

Biol Blood Marrow Transplant. 2017 Mar;23(3):405-411. doi: 10.1016/j.bbmt.2016.12.624. Epub 2016 Dec 19.

47.

Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C.

Bone Marrow Transplant. 2017 Apr;52(4):627-629. doi: 10.1038/bmt.2016.330. Epub 2016 Dec 19. No abstract available.

48.

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS.

Bone Marrow Transplant. 2017 Mar;52(3):400-408. doi: 10.1038/bmt.2016.265. Epub 2016 Dec 12.

49.

Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA.

Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. Epub 2016 Nov 7.

PMID:
27819684
50.

Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J.

Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 2016 Sep 13.

Supplemental Content

Loading ...
Support Center